APA

Mendel D. B., Laird A. D., Smolich B. D., Blake R. A., Liang C., Hannah A. L., Shaheen R. M., Ellis L. M., Weitman S., Shawver L. K. & Cherrington J. M. (20000725). Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. : Anti-cancer drug design.

Chicago

Mendel D B, Laird A D, Smolich B D, Blake R A, Liang C, Hannah A L, Shaheen R M, Ellis L M, Weitman S, Shawver L K and Cherrington J M. 20000725. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. : Anti-cancer drug design.

Harvard

Mendel D. B., Laird A. D., Smolich B. D., Blake R. A., Liang C., Hannah A. L., Shaheen R. M., Ellis L. M., Weitman S., Shawver L. K. and Cherrington J. M. (20000725). Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. : Anti-cancer drug design.

MLA

Mendel D B, Laird A D, Smolich B D, Blake R A, Liang C, Hannah A L, Shaheen R M, Ellis L M, Weitman S, Shawver L K and Cherrington J M. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. : Anti-cancer drug design. 20000725.